Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp and Venetoclax in Treatment-naive BPDCN
NCT07007052Phase 2Recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Immunotoxins, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tagraxofusp, venetoclax in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by French Innovative Leukemia Organisation. Started Dec 2025; status: recruiting.
02
Drugs
tagraxofuspvenetoclax
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT07007052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007052.